1. Inspira Technologies initiates $1.8 million share offering at $1.15 each. 2. A Standby Equity Purchase Agreement allows for $25 million in future capital. 3. Funds will support strategic operations and working capital needs. 4. Founders emphasize robust financial foundation for growth. 5. Regulatory filings are pending for the direct offering and SEPA.
FAQ
Why Bullish?
The share offering ensures immediate capital, enhancing financial stability and growth potential. Historical cases show that successful capital raises often lead to improved investor confidence and stock performance.
How important is it?
The article discusses new funding which could immediately impact stock performance and operational capacity. Immediate capital is critical for the company’s growth trajectory.
Why Short Term?
Immediate capital affects operational capabilities, but long-term gains depend on execution. Previous capital raises by medical firms often influence short-term price movements positively.
Inspira Technologies Announces $1.8 Million Direct Offering and Equity Financing Agreement
RA'ANANA, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW), a leader in life-support and diagnostic technologies, has entered into a definitive agreement for a registered direct offering of its ordinary shares, in addition to a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd.
Details of the Registered Direct Offering
Inspira Technologies has agreed to issue and sell 1,565,217 ordinary shares at a price of $1.15 per share. This offer is expected to garner gross proceeds of approximately $1.8 million and is anticipated to close on or about December 16, 2025, pending the fulfillment of customary closing conditions. The shares will be sold under a prospectus supplement that will be filed with the Securities and Exchange Commission (SEC) in connection with the Company’s shelf registration statement (Form F-3, File No. 333-289324), which was approved on December 12, 2025.
Standby Equity Purchase Agreement for Future Financing
Along with the direct offering, Inspira Technologies has established a SEPA with YA that allows the Company to sell up to $25 million of its ordinary shares over the next 36 months. This arrangement gives the Company the flexibility to draw on this capital as needed without any minimum purchase requirements. Sales under the SEPA will be made at Inspira's discretion, enabling opportunistic financing as necessary.
Use of Proceeds and Strategic Goals
The net proceeds from the registered direct offering and any future proceeds from the SEPA will be allocated for working capital and general corporate purposes. This includes supporting the Company’s strategic roadmap and planned operations.
“This financing creates a robust financial foundation for Inspira Technologies as we move decisively to translate our recent progress into meaningful commercial growth,” said Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies.
Ben-Noon emphasized that the immediate capital, combined with a flexible long-term equity facility, enhances the Company’s capability to advance its initiatives and support ongoing operations.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company that specializes in advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA™ ART100 system is approved for U.S. cardiopulmonary bypass procedures and ECMO (Extracorporeal Membrane Oxygenation) treatments outside the U.S. The Company is also developing the next-generation INSPIRA ART500 system and the HYLA™ proprietary blood sensor platform.
With a comprehensive portfolio, ongoing innovation, and strategic operational enhancements, Inspira Technologies is positioned as a key player in the life-support and MedTech sectors.
Forward-Looking Statements
This announcement contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. Such statements include expectations about capital access through the SEPA, the financial foundation created by the recent financing, and potential impacts on the Company’s strategic objectives. For more details, refer to the risk factors detailed in the Company’s Annual Report on Form 20-F.
Contact Information
For further inquiries, please contact Inspira Technologies:
- Email: info@inspirao2.com
- Phone: +972-9-9664485